19:33 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest promoting CTNNB1 citrullination or PAD2 expression could help treat colorectal cancer. Screening of approved drugs in HEK cell-based assays of CTNNB1 signaling and cell line-based citrullination...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Pilot trial data

An open-label pilot trial in 5 liver transplant patients showed that oral Alinia reduced HCV viral load in all patients during the first 72 hours post-transplant. However, HCV RNA levels were similar to pre-transplant levels...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II start

Next half, Intercell AG (VSE:ICLL; OTCQX:INRLY, Vienna, Austria) and Romark will begin a European Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's nitazoxanide with or without Pegasys...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II data

Chugai, a subsidiary of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), has exclusive rights to develop and commercialize Alinia in Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Alinia for oral suspension and Alinia tablets...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II started

Romark began a double-blind, placebo-controlled, U.S. Phase II trial (RM01-2027) in 440 patients to evaluate 500 mg oral Alinia twice daily for 5 days. Chugai, a subsidiary of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), has exclusive...
08:00 , Jan 7, 2010 |  BC Innovations  |  Targets & Mechanisms

HCV cache: the list

Researchers at The Scripps Research Institute have used a cell-based model of HCV infection to identify compounds on the market or in development for other indications that could be repurposed to treat HCV. 1 But...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Extraneal regulatory update

FDA approved a boxed warning to the label of Extraneal peritoneal dialysis solution to warn of dangerous drug-device interaction. The boxed warning states that blood glucose measurement in patients receiving Extraneal must be done with...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Controlled release nitazoxanide: Phase II data

Data from the double-blind, placebo-controlled Phase III OPTIMA HCN-2 trial in 41 treatment-naïve patients with chronic HCV genotype 4 showed that twice-daily 675 and 1,350 mg controlled release nitazoxanide produced RVR rates of 59% and...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Controlled release nitazoxanide: Phase I data

In the double-blind, crossover Phase I OPTIMA HCN-1 trial in 12 healthy volunteers, twice-daily 675 and 1,350 mg controlled release nitazoxanide produced trough plasma concentrations of tizoxanide, the active metabolite of nitazoxanide, that were 3...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II data

In an open-label, Egyptian Phase II trial in 44 treatment-naïve patients with chronic HCV, a 4-week lead-in with twice-daily 500 mg Alinia followed by 36 weeks of Pegasys peginterferon alfa-2a plus Alinia met the primary...